rss
J Neurol Neurosurg Psychiatry 85:60-66 doi:10.1136/jnnp-2013-305246
  • Multiple sclerosis
  • Review

Ultra-high-field MR imaging in multiple sclerosis

  1. Maria A Rocca1,2
  1. 1Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
  2. 2Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
  3. 3Division of Clinical Neurology, Nottingham University Hospitals, University of Nottingham, Nottingham, UK
  4. 4Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, New York, USA
  5. 5Department of Neurology, Radiology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
  6. 6Department of Radiology, A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
  7. 7Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
  1. Correspondence to Professor Massimo Filippi, Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan 20132, Italy; filippi.massimo{at}hsr.it
  • Received 22 February 2013
  • Revised 29 April 2013
  • Accepted 3 May 2013
  • Published Online First 27 June 2013

Abstract

In multiple sclerosis (MS), MRI is the most important paraclinical tool used to inform diagnosis and for monitoring disease evolution, either natural or modified by treatment. The increased availability of ultra-high-field magnets (7 Tesla or higher) gives rise to questions about the main benefits of and challenges for their use in patients with MS. The main advantages of ultra-high-field MRI are the improved signal-to-noise ratio, greater chemical shift dispersion, and improved contrast due to magnetic susceptibility variations, which lead to increased sensitivity to the heterogeneous pathological substrates of the disease. At present, ultra-high-field MRI is mainly used to improve our understanding of MS pathogenesis. This review discusses the main achievements that have so far come from the use of these scanners, which are: better visualisation of white matter lesions and their morphological characteristics; an improvement in the ability to visualise grey matter lesions and their exact location; the quantification of ‘novel’ metabolites which may have a role in axonal degeneration; and greater sensitivity to iron accumulation. The application of ultra-high-field systems in standard clinical practice is still some way off since their role in the diagnostic work-up of patients at presentation with clinically isolated syndromes, or in monitoring disease progression or treatment response in patients with definite MS, needs to be established. Additional challenges remain in the development of morphological, quantitative and functional imaging methods at these field strengths, techniques which may ultimately lead to novel biomarkers for monitoring disease evolution and treatment response.

Podcasts
Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article